SAREPTA THERAPEUTICS INC (SRPT) Stock Price & Overview

NASDAQ:SRPT • US8036071004

Current stock price

22.24 USD
+0.34 (+1.55%)
Last:

The current stock price of SRPT is 22.24 USD. Today SRPT is up by 1.55%. In the past month the price increased by 24.01%. In the past year, price decreased by -57.08%.

SRPT Key Statistics

52-Week Range10.415 - 64.8
Current SRPT stock price positioned within its 52-week range.
1-Month Range16.27 - 23.85
Current SRPT stock price positioned within its 1-month range.
Market Cap
2.335B
P/E
N/A
Fwd P/E
7.36
EPS (TTM)
-6.65
Dividend Yield
N/A

SRPT Stock Performance

Today
+1.55%
1 Week
+0.64%
1 Month
+24.01%
3 Months
-8.10%
Longer-term
6 Months -0.95%
1 Year -57.08%
2 Years -82.71%
3 Years -82.16%
5 Years -69.09%
10 Years +54.33%

SRPT Stock Chart

SAREPTA THERAPEUTICS INC / SRPT Daily stock chart

SRPT Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to SRPT. When comparing the yearly performance of all stocks, SRPT is a bad performer in the overall market: 90.23% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SRPT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SRPT. Both the profitability and financial health of SRPT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SRPT Earnings

On February 25, 2026 SRPT reported an EPS of -3.93 and a revenue of 442.93M. The company missed EPS expectations (-213.05% surprise) and beat revenue expectations (10.8% surprise).

Next Earnings DateMay 4, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$3.93
Revenue Reported442.934M
EPS Surprise -213.05%
Revenue Surprise 10.80%

SRPT Forecast & Estimates

33 analysts have analysed SRPT and the average price target is 30.27 USD. This implies a price increase of 36.12% is expected in the next year compared to the current price of 22.24.

For the next year, analysts expect an EPS growth of 145.42% and a revenue growth -18.84% for SRPT


Analysts
Analysts68.48
Price Target30.27 (36.11%)
EPS Next Y145.42%
Revenue Next Year-18.84%

SRPT Groups

Sector & Classification

SRPT Financial Highlights

Over the last trailing twelve months SRPT reported a non-GAAP Earnings per Share(EPS) of -6.65. The EPS decreased by -391.67% compared to the year before.


Income Statements
Revenue(TTM)2.20B
Net Income(TTM)-713.41M
Industry RankSector Rank
PM (TTM) N/A
ROA -21.3%
ROE -62.55%
Debt/Equity 0.73
Chartmill High Growth Momentum
EPS Q2Q%-362%
Sales Q2Q%-32.73%
EPS 1Y (TTM)-391.67%
Revenue 1Y (TTM)15.58%

SRPT Ownership

Ownership
Inst Owners89.94%
Shares104.99M
Float99.57M
Ins Owners5.12%
Short Float %22.99%
Short Ratio7.67

About SRPT

Company Profile

SRPT logo image The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees.

Company Info

IPO: 1997-06-04

SAREPTA THERAPEUTICS INC

215 First Street, Suite 415

Cambridge MASSACHUSETTS 02142 US

CEO: Douglas S. Ingram

Employees: 835

SRPT Company Website

SRPT Investor Relations

Phone: 16172744000

SAREPTA THERAPEUTICS INC / SRPT FAQ

What does SAREPTA THERAPEUTICS INC do?

The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees.


Can you provide the latest stock price for SAREPTA THERAPEUTICS INC?

The current stock price of SRPT is 22.24 USD. The price increased by 1.55% in the last trading session.


What is the dividend status of SAREPTA THERAPEUTICS INC?

SRPT does not pay a dividend.


What is the ChartMill technical and fundamental rating of SRPT stock?

SRPT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Is SAREPTA THERAPEUTICS INC (SRPT) expected to grow?

The Revenue of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -18.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is SAREPTA THERAPEUTICS INC worth?

SAREPTA THERAPEUTICS INC (SRPT) has a market capitalization of 2.33B USD. This makes SRPT a Mid Cap stock.